Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.55 |
| ▸ | CTSG | P08311 | 1/20 | 0.55 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.55 |
| ▸ | CMA1 | P23946 | 1/20 | 0.55 |
| ▸ | MME | P08473 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CCR1 | P32246 | 2/20 | 0.52 |
| ▸ | GPR132 | Q9UNW8 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9829285 | 1.00 | RAB9A (0.60) | RAB9ANPC1LMNACA2TDP1 | |
| SCHEMBL18560572 | 0.92 | NPC1 (0.73) | RAB9ANPC1LMNACA2ALDH1A1 | |
| SCHEMBL10668269 | 0.90 | CA2 (0.68) | RAB9ANPC1LMNACA2TDP1 | |
| SCHEMBL186937 | 0.90 | CA2 (0.68) | RAB9ANPC1LMNACA2TDP1 | |
| SCHEMBL186935 | 0.90 | CA2 (0.68) | RAB9ANPC1LMNACA2TDP1 | |
| SCHEMBL24064866 | 0.89 | CA2 (0.63) | RAB9ANPC1LMNACA2TDP1 | |
| Ammonia Solution, Strong SCHEMBL11218438 | 0.89 | CA2 (0.67) | RAB9ANPC1LMNACA2TDP1 | |
| SCHEMBL10119206 | 0.87 | CTSL (0.61) | CA2HPGDCA12CA1CA9 | |
| SCHEMBL7759090 | 0.87 | CA2 (0.61) | RAB9ANPC1LMNACA2TDP1 | |
| SCHEMBL29036089 | 0.87 | CA2 (0.61) | RAB9ANPC1LMNACA2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1036832-C | Composition containing a penem or carbapenem artibiotic and the use of the same | SANKYO CO (JP) | 1997-12-31 | — | — | CN | claimed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | claimed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | claimed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | claimed |
| CN-86107574-A | Compositions containing penem or carbapenem antibiotics and their use | — | 1987-05-20 | — | — | CN | claimed |
| CN-118613484-A | Antifolate linker-drug and antibody-drug conjugates | 拜奥迪斯私人有限公司 | 2024-09-06 | — | — | CN | disclosed |
| CN-118026886-A | Synthesis method of various functionalized beta-amino acid esters | 国科大杭州高等研究院 | 2024-05-14 | — | — | CN | disclosed |
| US-7538190-B2 | Methods for the synthesis of two or more dicarba bridges in organic compounds | POLYCHIP PHARMACEUTICALS PTY LTD (AU) | 2009-05-26 | — | — | US | disclosed |
| US-20070197771-A1 | Methods for the synthesis of two or more dicarba bridges in organic compounds | SYNGENE LIMITED (AU) | 2007-08-23 | — | — | US | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197771-A1 | Methods for the synthesis of two or more dicarba bridges in organic compounds | OTC, NBAS, IDH2 | RAB9A 3416/4885NPC1 1424/4885LMNA 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.